retatrutide nonalcoholic fatty liver disease nash trial Retatrutide, the triple G, Glucagon-GIP-GLP-1 based triagonist produces substantial resolution of liver fat #NAFLD in PPL with #obesity #ADA2023 @ADA_DiabetesPro @AmDiabetesAssn #NASH trial coming Efficacy and safety of subcutaneous
Description
This is not fat gain, but it can devastate motivation if you do not understand what is happening
This isnt a radical ideaits what I was taught in graduate school by Sid Strickland.
Research has shown that the glucagon component specifically targets visceral fat reduction and hepatic lipid metabolism, which are areas where single-agonist compounds show less activity
But all this might not stop you worrying about cyclosporiasis
Still, each one can lead to reduced persistence over time
